This result aligns with a previous clinical study involving 95 patients with DM and coronary artery disease, which demonstrated empagliflozin’s significant anti-inflammatory effects, evidenced by lower IL-6 concentration in patients treated with oral empagliflozin (Gohari et al., 2022). This evidence concerns the gene IL6 and coronary artery disorder.